Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Julphar
Citi
Fish and Richardson
Harvard Business School
Fuji
UBS
US Department of Justice
McKinsey

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,990,100

« Back to Dashboard

Which drugs does patent 5,990,100 protect, and when does it expire?

Patent 5,990,100 protects CLOBEX and TOPICORT and is included in two NDAs.
Summary for Patent: 5,990,100
Title: Composition and method for treatment of psoriasis
Abstract:Pharmaceutical compositions and methods for use in the treatment of psoriasis, having isopropyl myristate as a first active ingredient and a different anti-psoriatic agent as a second active ingredient; preferably they are combined in the same pharmaceutical composition.
Inventor(s): Rosenberg; E. William (Memphis, TN), Glenn; Thomas M. (Mobile, AL), Skinner, Jr.; Robert B. (Memphis, TN), Noah; Patricia W. (Germantown, TN)
Assignee: Panda Pharmaceuticals, L.L.C. (Memphis, TN) The University of Tennessee Research Corporation (Knoxville, TN)
Application Number:09/143,146
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 5,990,100

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp CLOBEX clobetasol propionate SPRAY;TOPICAL 021835-001 Oct 27, 2005 AT RX Yes Yes ➤ Sign Up ➤ Sign Up Y TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS. ➤ Sign Up
Taro TOPICORT desoximetasone SPRAY;TOPICAL 204141-001 Apr 11, 2013 AT RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,990,100

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,886,038 Composition and method for treatment of psoriasis ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Deloitte
Boehringer Ingelheim
Farmers Insurance
Merck
Cantor Fitzgerald
Chinese Patent Office
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.